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Abstract
After the initial report in 2014 on T1-weighted (T1w) hyperintensity of deep brain nuclei following serial injections of linear
gadolinium-based contrast agents (GBCAs), a multitude of studies on the potential of the marketed GBCAs to cause T1w
hyperintensity in the brain have been published. The vast majority of these studies found a signal intensity (SI) increase for
linear GBCAs in the brain—first and foremost in the dentate nucleus—while no SI increase was found for macrocyclic GBCAs.
However, the scientific debate about this finding is kept alive by the fact that SI differences do not unequivocally represent the
amount of gadolinium retained. Since the study design of the SI measurement in various brain structures is relatively simple,MRI
studies investigating gadolinium-dependent T1w hyperintensity are currently conducted at multiple institutions worldwide.
However, methodological mistakes may result in flawed conclusions. In this position statement, we assess the methodological
basis of the published retrospective studies and define quality standards for future studies to give guidance to the scientific
community and to help identify studies with potentially flawed methodology and misleading results.
Key Points
• A multitude of studies has been published on the potential of the marketed GBCAs to cause T1w hyperintensity in the brain.
• The gadolinium-dependent T1w hyperintensity in the brain depends on patient’s history, types of GBCAs used (i.e., linear vs.
macrocyclic GBCAs) and MR imaging setup and protocols.
• Quality standards for the design of future studies are needed to standardize methodology and avoid potentially misleading
results from retrospective studies.
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Background and framework
In 2014, Kanda et al [1] reported a correlation between the
number of gadolinium-based contrast agent (GBCA) injections
and the increase of the dentate nucleus (DN)-to-pons and
globus pallidus (GP)-to-thalamus signal intensity (SI) ratios
on unenhanced T1-weighted (T1w) magnetic resonance imag-
ing (MRI). Subsequent studies on human tissue found a posi-
tive correlation between the MRI signal changes and gadolini-
um concentration. Retrospective analysis at a multitude of sites
revealed that gadolinium retention in brain structures in patients
with normal renal function and intact blood-brain barrier has
been occurring for the last 25 years without being noticed.
Themajority ofMRI studies [1–63]were focused onSI chang-
es in the DN. Due to the relatively simple setup of such studies,
retrospective imaging studies have been conducted worldwide at
multiple sites. These studies provided evidence that (i) linear
GBCAs are correlated with a SI increase in the DN if a certain
number of injections (probably 5–6 injections) is exceeded; (ii)
non-ionic linear GBCA gadodiamide causes a stronger SI in-
crease than ionic linear GBCAs gadopentetate and gadobenate,
and (iii) macrocyclic GBCAs are not or only weakly associated
with SI increase compared to linear GBCAs (Fig. 1).
Notably, the majority of dentate studies found the SI increase
to be dose-dependent for linear agents with a greater deposition
associated especially with the weaker chelates such as
gadodiamide (Omniscan®, GE Healthcare) and gadopentetate
dimeglumine (Magnevist®, Bayer Healthcare) and in the pres-
ence of renal impairment. Indeed, the more stable macrocyclic
GBCAs, gadoteridol (ProHance®, Bracco Imaging), gadoterate
meglumine (Dotarem®, Guerbet), and gadobutrol (Gadovist®,
Bayer Healthcare), have not been associated with substantial
MRI changes in the majority of published studies, suggesting that
the molecular structure of the GBCA ligand, whether linear or
macrocyclic, is a crucial factor for the increase in signal intensity.
When interpreting MRI studies, the inherent limitations of this
technique to assess gadolinium in human tissues should be
acknowledged.
A comparison between different imaging studies is
often hampered by different methodological approaches,
and stakeholders’ interests can influence the debate by
specifically presenting the publications that provide the
desired results. The lack of systematic collection of da-
ta, the limited number of patients in single-center stud-
ies, and the varying technical setup and MRI sequence
parameters among different institutions make data meta-
analysis challenging if not impossible.
The current consensus paper aims to provide a guideline
for retrospective MRI studies to guarantee a minimum level of
standardization to achieve higher accuracy and maximize re-
producibility. We highly urge editors and authors to comply
with these standards to avoid the dilution of the scientific
debate by flawed publications.
Scientific context
In the period between 2014 and 2018, 63 original retrospec-
tive studies [1–63] were published all over the world, regard-
ing the relationship between T1 high SI on brain MRI studies
and exposure to intravenously injected GBCAs.
Available literature found that the signal changes in certain
central nervous system structures identified with MRI, first
and foremost the DN, correlated positively with the exposure
to linear GBCAs. It is under debate if macrocyclic GBCAs
can cause any SI increase (Fig. 1).
Even though retrospective studies can be highly qualified,
the level of evidence provided from any study reporting on T1w
hyperintensity depends primarily on uniform imaging protocol,
scanners, time periods in which the follow-up examinations are
performed and the number of included patients. Studies
assessing identical imaging parameters and MR scanners at
regular follow-up intervals provide a much higher level of ev-
idence than studies that do not control for these parameters.
Even though evidence from retrospective studies is generally
classified as levels 3b (individual case-control studies), 4 (case
series), and 5 (expert opinion) according to the Centre for
Evidence-Based Medicine, Oxford, they can therefore provide
a higher level of evidence than prospective studies that do not
control for these parameters. Given the current body of evi-
dence, it is likely that prospective, blind, controlled randomized
studies would not significantly change the consistent results of
the numerous available retrospective studies on the potential of
GBCAs to cause T1w hyperintensity. Nevertheless, type I (false
positives findings) and type II errors (false negative findings)
may flaw study results and data interpretation (Table 1). Editors
need to evaluate methodology used in retrospective studies
across the world due to the heavily increasing number of pub-
lished studies on this topic.
Although no definitive symptoms or diseases linked to the
T1w hyperintensity in the gadolinium-exposed population
have been reported, data on long-term effects is still limited,
and further research is needed [64].
To date, nephrogenic systemic fibrosis (NSF) still repre-
sents the only well-established clinical entity related to toxic
effects of gadolinium and occurs in patients with severe im-
pairment of renal function after exposure to certain GBCAs.
Several papers have been published recently and presumably
many will follow as radiological institutions are interested to
Fig. 1 Color map of currently published retrospective clinical studies on
gadolinium-related brain T1w hyperintensity. Red: dentate nucleus (DN)
signal increase with visible hyperintensity (unconfounded GBCAs);
Light red: DN signal increase or visible hyperintensity (confounded
GBCAs); Orange: DN T1w signal intensity increase without visible
hyperintensity (unconfounded GBCAs); Light green: No DN signal in-
crease or visible hyperintensity (confounded GBCAs); Green: No DN
signal increase with no visible hyperintensity (unconfounded GBCAs)
b
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explore their available database and verify the prevalence of
MRI findings or clinical correlates in the whole or in specific
populations after repeated exposure to GBCAs.
While radiologists consider providing diagnostic imaging
with contrast-enhanced MRI a professional and ethical obliga-
tion, there is an equal obligation to protect patients from the
potential risk of side effects related to this diagnostic procedure.
The current guidelines adopted by regulatory agencies
(EMA, European Medicine Agency; FDA, Food and Drug
Administration) and scientific societies (ESUR, European
Society of Urogenital Radiology; ACR, American College
of Radiology etc.) are relevant and of great importance in
the clinical management of patients with renal insufficiency.
However, methodological aspects are crucial to harmonize
data and support decision-making both at preclinical [65]
and clinical level [66]. In fact, recommendations on how to
design and report data from clinical studies on gadolinium-
induced brain T1 hyperintensity are currently missing.
Evidence from preclinical research
The appearance of T1w hyperintensity in the dentate nucleus of
the cerebellum and in other brain areas is under debate as it has
been used as an MRI correlate of gadolinium deposition in the
brain and to compare different GBCAs. The data available from
the scientific literature may appear not consistent among MRI
studies; the retrospective nature of the studies and variables de-
pending on patient’s history, types of GBCAs used (confounded
vs. unconfounded), and MRI protocols affect the results.
The currently prevailing theory of the development of
gadolinium-dependent T1w hyperintensity is based on animal
studies that found gadolinium in three different forms: the
intact chelate, precipitated gadolinium, and gadolinium bound
to macromolecules [65, 67, 68]. While the intact chelate was
found for both—linear and macrocyclic chelates—precipitat-
ed gadolinium or gadolinium bound to macromolecules was
found exclusively for linear GBCAs [69]. A recent study re-
ported a washout of the intact chelate for the macrocyclic
GBCA gadoterate (with no gadolinium above the level of
detection after 6 months) while pharmacokinetic analysis sug-
gested that gadolinium bound to macromolecules might stay
permanently in the brain [68, 70]. Since, at least at the mag-
netic fields used in clinical practice, precipitated gadolinium
should not cause T1-shortening and gadolinium bound to
macromolecules causes a strong T1-effect, it is very likely that
gadolinium released from the less stable linear agents that
subsequently binds to macromolecules is the cause of the ob-
served T1w hyperintensity seen with linear GBCAs. The ac-
cumulation of gadolinium in the DN and other structures
might further be explained by the increased metal content in
these areas, facilitating transmetallation.
In contrast, the intact chelate might only cause a temporary
signal intensity increase during the washout phase of the che-
late. The pathway of the intact complex through the brain is
not completely understood, but there is accumulating evi-
dence that gadolinium gets into the CSF through the choroid
plexus and reaches the brain through the glymphatic system. It
is important to point out that animal studies provided evidence
that a comparable amount of all GBCAs reaches the brain and
might cause T1w hyperintensities on its way through the
glymphatic system [68, 71]. However, T1w hyperintensities
in metal-rich areas should exclusively appear if the gadolini-
um is released from its complex. Hence, it is not expected that
the intact chelate will accumulate in the DN or other metal-
rich structures. These considerations underline the importance
of the appearance of a visible dentate hyperintensity on
unenhanced T1w images and do not give a theoretical basis
for a long-lasting signal intensity increase (that is not caused
by the temporary presence of the intact chelate) if no gadolin-
ium accumulation can be found.
It should be emphasized that the T1w signal intensity in-
crease in the brain might represent an indicator of the gadolin-
ium release in the whole body. Especially the bone and skin
[72–74] have been identified as areas of gadolinium deposition.
In summary, multiple biochemical and physiological mecha-
nisms can modulate relaxivities in the living tissues such as mac-
romolecular binding, water access, aggregation/precipitation, and
cellular internalization. These effects are complex and do not
affect T1, T2, and T2* relaxivity the same way. Thus, a fraction
Table 1 Type I and Type II Errors
in Data Interpretation of Signal
Intensity of the Dentate Nucleus
and other brain sites after
repetitive administrations of
GBCAs
Type I errors Type II errors
Disease mechanisms MRI Technical aspects (e.g., GRE vs. SE sequences)
Age effects Age effects
Confounded GBCAs (e.g., exposure to linear GBCAs
in studies focused on macrocyclic GBCAs)
Confounded GBCAs (e.g., exposure to macrocyclic
GBCAs in studies focused on linear GBCAs)
Presence of other minerals (e.g., Ca2+, Fe3+, Cu3+, Mn2+) Fe3+ effects on SI on T1 weighted images
Macromolecular complexes with high T1 relaxivity Lower T1 relaxivity at higher magnetic fields
(e.g., 3.0 T vs. 1.5 T)
Absence of signal from precipitated Gd3+
salts in tissue
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of the deposited gadoliniumwill remain invisible on T1w images.
Multiparametric MRI analyses (e.g., with combination of T1, T2,
and T2* or quantitative magnetic susceptibility mapping) may be
used in future studies to disentangle these combined effects.
Recommendations
Results of the analysis of current literature indicate that knowl-
edge gaps exist and recommendations are needed to systemati-
cally collect data in the experimental design of scientific studies
[64, 75]. In November 2016 and 2017, the 1st and 2nd European
Gadolinium Retention Evaluation Consortium (GREC) meet-
ings were held in Naples (Italy) and Lisbon (Portugal), respec-
tively, under the patronage of the European Society of
Neuroradiology, with the intent to join the efforts of scientists
from academy and industry and improve the understanding of
the mechanisms of gadolinium retention/deposition/accumula-
tion in the brain and non-brain tissues and, if any, its relationship
with clinical symptoms in patients exposed to GBCAs [64]. In
2016, the GREC commissioned a Task Force to review the
evidence regarding the gadolinium-dependent T1w
hyperintensity in the brain and the methodology used to assess
gadolinium retention in the brain in clinical studies.
In developing this position statement, the GREC and its Task
Force assessed the methods applied to the measurement of T1w
high SI in the brain in retrospective studies and found a lack of
consistency in methodology across different institutions.
National and international scientific societies may use this
recommendation to solicit and design harmonized multi-
center studies that are aimed to explore indirectMRI measures
of gadolinium retention/deposition in the brain. Regulatory
agencies and scientific journal editors could use these recom-
mendations to verify the methodology used in clinical studies.
Finally, scientists will find a reference and a tool for the design
and development of clinical studies.
Recommendations for the study design
and interpretation of MRI results in clinical
studies
Since restriction policies on the use of contrast agents must be
evidence-based and excessive restrictions can have negative
implications for healthcare, the GREC Task Force proposes
the following specific suggestions (summarized in Table 2) to
conduct clinical studies that assess brain MRI changes follow-
ing repetitive intravenous administrations of GBCAs and to
increase data homogeneity among different institutions.
1. GBCA administration has to be registered and traced over
time to allow comparison of gadolinium retention-
dependent signal. Institutions must have unequivocal
proof of the type and dose of GBCA administered in each
examination. If an institution has shifted from the single
use of one GBCA compound to the single use of another
one, shift dates should be clearly defined and document-
ed. Authors have to exclude exposure to other GBCAs in
the assessed period unequivocally by chart review. If they
cannot exclude exposure to other GBCAs in the assessed
period of time, they clearly have to state this.
2. Only SI differences between two specific MRI studies or
intra-individual serial evaluation of multiple MRI stud-
ies should be assessed. Since absolute SIs are not reliable
to assess gadolinium retention based on the influence of
many parameters such as coil sensitivity, coil filling fac-
tor, head positioning within the coil, coil tuning/
matching drift, MRI parameter drift, hardware and soft-
ware gain, only relative SIs should be assessed. If avail-
able, a control group which got either a different GBCA
or no GBCAs at all might be assessed.
3. Since the relevant parameter is the SI change, patients with
pre-existing hyperintensity due to the prior injection of lin-
ear GBCAs can be included even if they display T1w high
signal intensity at baseline. However, the authors need to
provide documentation or state that they cannot exclude
that the patients received other GBCAs prior to the inclu-
sion in the study. A subgroup analysis may need to be
conducted to exclude influence of previous GBCA injec-
tions or other confounding disease processes.
4. The average number of injections and the time between
injections need to be documented clearly.
5. The DN has been shown to be the most sensitive struc-
ture for gadolinium deposition. Thus, studies that assess
gadolinium retention in the brain should focus on this
structure. If no SI increase is found in the DN, it is un-
necessary to assess any further structure in the brain. If
an SI increase in the DN is found, further structures
(such as the GP) might be assessed.
6. The DN-to-pons ratio should be assessed in all studies
since this is the most often used ratio in previous studies.
Additionally, the DN-to-middle cerebellar peduncle
(MCP) ratio can be used. The reliability of these mea-
sures is mainly based on the observation of less gadolin-
ium deposition in the pons and middle cerebellar pedun-
cles compared to DN in autopsy studies.
7. Regions of interest (ROI)-based approaches have been the
most used and are expected to be used in future retrospec-
tive analyses. Generally, an extremely low inter-rater vari-
ability of this approach has been reported in previous stud-
ies if conducted appropriately. Since the DN is better
depicted on T2w or diffusion-weighted images, these
should be used as reference for placing ROIs. Since ROI
drawing remains operator-dependent and used to obtain
relative SI ratios, intra-rater and inter-rater agreement might
be conducted as internal quality check.
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8. Performance of automatic segmentation techniques in
comparison to ROI techniques might be considered.
Due to the low reported inter-rater variability of the
ROI-based approach, it is questionable if the automatic
approaches might provide additional value. However,
this approach could be useful for the assessment of large
datasets and of studies that provided unexpected results
(e.g., high SI increase without any visible hyperintensity
or no SI changes with visible hyperintensity).
9. Quantitative analyses such as T1 and T2 relaxivity map-
ping may be used additionally. It is currently unclear if
they can provide additional value.
10. Since several technical parameters can affect the MR
signal, investigators should indicate in the methods sec-
tion a detailed table with the MR parameters: B0 static
magnetic field, MR magnet vendor, coil type and num-
ber of coil channels, gradient strength, type of pulse
sequence (e.g., Spin Echo (SE), Fast/Turbo Spin Echo
(FSE or TSE), Gradient Echo (GRE), Inversion
Recovery (IR), Magnetization Prepared Gradient Echo
(MP-RAGE), type of prepulse, type of phase encoding
(2D or 3D), Fourier transformation algorithm, repetition
time (TR), echo time (TE), inversion time if applicable,
flip angle, slice thickness, voxel volume, field of view,
matrix, number of averages, and receiver bandwidth.
11. The SI ratio difference can only be calculated between
MRI examinations that use identical imaging parameters
and field strengths. Variation for TR and TE values
between exams should be kept as small as possible. The
maximum threshold of 3.5% of variation has been pro-
posed as acceptable [24]. For high levels of parameter
variations, subgroup analyses need to be performed.
Variations of TR and TE above 15% should be excluded
[24]. The SI ratio difference cannot be calculated between
different pulse sequences or magnetic field strengths.
12. All studies should check if there is a visible SI increase in the
DN in all patients that cannot be explained by confounders.
Studies that report a high SI increase without corresponding
visibility of this increasemight be flawed (e.g., measurement
of aging-related changes). The same holds true for studies
that find clear visible SI increase in some patients but did not
find a statistically significant SI increase.
13. Even though no clear correlation between SI increase
and symptoms has been shown for most diseases, as a
general recommendation, it is appropriate to evaluate
and compare groups of patients with similar diagnoses.
The available data do not allow understanding, at this
point, of what is the contribution of the underlying path-
ologic process (brain tumors, chronic inflammatory dis-
eases) on gadolinium retention and deposition. In addi-
tion, pediatric patients should always be treated as a
distinct group for analysis.
14. Age of the patients included into retrospective studies
should always be reported. This is crucial especially in
pediatric patients that should be treated as a distinct
group for analysis.
Table 2 Recommendations to
design retrospective studies on
changes of signal intensity on
unenhanced T1-weighted images
after repetitive intravenous ad-
ministrations of GBCAs
Institution - Provide unequivocal proof of the type and dose of GBCA
used in each examination.
Patients - Group patients by age; separate pediatric (< 18 years) from adults.
- Group patients by disease and report on interval treatment in the period of study
- If a T1w SI increase is observed, exclude conditions or disorders commonly
associated with brain deep gray matter T1 hyperintensity (parenteral feeding,
exposure to manganese, porto-systemic shunts, neurofibromatosis etc.)
GBCAs - Exclude the exposure to other GBCAs than that object of the study
in the assessed period of time.
- State clearly the average number of injections and the time between injections
MR imaging parameters - Indicate MR technical parameters in the methods section as prescribed
in recommendation 9.
- Do not calculate SI change between different MR pulse sequences.
- Accept a variation for TR and TE values up to 3.5; changes above 15% should
be excluded. Subgroup analyses should be conducted to exclude a potential bias.
Quantitative ratios
measurements
- Report on DN-to-pons ratios.
- Additionally you might use DN-to-middle cerebellar peduncle ratio.
- Intra-rater and inter-rater agreement for ROI measurements are generally
very high. They might be conducted for internal quality check.
SI change - Calculate SI change between scans with identical field strength.
- Assess exclusively SI differences/changes measured with comparable
technical parameters (see below)
- Compare signal intensities of single MRI studies only between age-matched
groups without GBCAs exposure and with identical imaging parameters
at the same MRI scanner.
GBCA gadolinium-based contrast agent, SI signal intensity
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15. In studies that report a SI increase, it is mandatory to
consider the confounders of conditions that increase
the concentration of manganese in the deep gray matter
(parenteral feeding, exposure to manganese, porto-
systemic shunt) or certain disorders associated with an
increase of the SI of the basal ganglia (neurofibromatosis
type I, metabolic disorders, hypoxic-ischemic encepha-
lopathy, etc.). The influence of radiation as a confounder
is still a topic under investigation [52].
Conclusions
There is a broad consensus that radiologists should use
GBCAs with the minimum effective dosage and only when
strictly clinically indicated. At the same time, every effort
should be made to protect patients from any side effect related
to retention or exposure to GBCAs, and concern for public
safety is paramount, particularly in children and patients who
need several follow-up exams.
It must be underlined that there is currently no evidence of
clinical consequences after exposure and retention of gadolin-
ium in brain and non-brain tissues of patients with normal
renal function, but any potential gadolinium-induced toxicity
should also not be underestimated.
The current recommendations are a joint international ef-
fort (GREC) to increase the comparability of the huge number
of retrospective studies that are currently published on SI in-
crease on T1wMRI following serial injections of GBCAs.We
encourage authors to follow these recommendations and edi-
tors and reviewers to evaluate the methodology of the papers
submitted for publication to peer-reviewed journals as there is
a need of data homogeneity and standardization on this topic.
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